Transaction #18646 · Form 4 · 0001493152-25-027329
Immix Biopharma, Inc. · Stock award · Stock Option (Right to Buy)
Immix Biopharma, Inc. · Transacted November 21, 2025 · Filed December 11, 2025
What does this filing report?
An SEC Form 4 filing for Immix Biopharma, Inc. records a stock award involving Stock Option (Right to Buy) on November 21, 2025. The reported quantity was 39,643. The filing date is December 11, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Immix Biopharma, Inc.
- Company CIK
- 0001873835
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 39,643
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 39,643
- Ownership description
- Not reported
- SEC acceptance time
- Dec 11, 2025, 8:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- CHANG NANCY T ↗
Director
CIK 0001135041
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 39,643
- Conversion / exercise price
- 4.33
- Exercise date
- Not reported
- Expiration date
- November 21, 2035
Filing footnotes & remarks
- F1
- Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. Dr. Chang disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.
- F2
- The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer and the terms of a Stock Option Agreement entered into to evidence the award.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.